HD-OPM Archive
Topics › Statins

Statins may lower risk of certain cancers and synergize with some cancer treatments

Louis Nervegna · Sep 20, 2024 · ♥ 10 reactions · 3 comments · original Facebook post
StatinsCancer
AI summary & key facts

Louis says there is considerable evidence that statins lower risk of certain cancers and may work with cancer treatments. The shared blog post argues statins are better supported than natural alternatives and mentions dipyridamole/statin and statin/metformin combinations. No specific trials are named.

There is quite a bit of evidence that statins lower the risk for certain cancers. They may also synergize with some cancer treatments.

#statincancerHD #statinsHD #cancerHD

Natural Alternatives or Statins?

Many people are swapping statins for natural cholesterol-lowering supplements, but is it the right choice?

Ultimately, both statins and natural supplements offer unique benefits and drawbacks. If you're a cancer patient, it's crucial to weigh your choices as you have a condition that means you need an effective option. It is important to choose something (natural or pharmaceutical) that may synergise with other treatments to have the best effect. Finally more scientific studies back up the dipyridamole/statin combinations as well as the synergy between statins and metformin.
You should carefully weigh up your choices and seek medical advice from a doctor. Statins have a huge amount of evidence against cancer but a combination might be the most effective approach.

To read my blog in full about some of the options available click below and if you have thoughts on it please comment if you have done well with either approach. Blog: Swapping your statin for natural products – are you doing the right thing? – How… (howtostarvecancer.com)

#cancertreatment #cancertreatments #repurposeddrugs #metformin #statins #cholesterollowering #integrativehealth #integrativecancercare

No photo description available.
← newer: FoundMyFitness episode on microplastics in the brain, body aolder: Economist: gene-editing drugs for cardiovascular disease are →